[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Ach T, Thiemeyer D, Hoeh AE, Schaal KB, Dithmar S: Intravitreal bevacizumab for retinal capillary haemangioma: longterm results. Acta Ophthalmol; 2010 Jun;88(4):e137-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Follow-Up Studies. Humans. Injections. Retreatment. Visual Acuity / physiology. Vitreous Body. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681788.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


2. Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R: Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol; 2005 Mar;123(3):328-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy.
  • OBJECTIVE: To investigate the efficacy of verteporfin and photodynamic therapy in the treatment of large retinal capillary hemangiomas.
  • METHODS: Case reports of 3 patients with large retinal capillary hemangiomas treated with photodynamic therapy using verteporfin.
  • Modified protocols included shorter verteporfin infusion times and longer light exposure times.
  • All cases had associated exudative retinal detachments involving the macula.
  • Cases 1 and 2 were classic endophytic retinal capillary hemangiomas.
  • Case 3 was a reactive retinal capillary hemangioma.
  • Case 1 had 2 photodynamic therapy treatments, and after 8 months, visual acuity improved to 20/40.
  • Two years after initiating photodynamic therapy, the visual acuity was 20/30 and there was no reperfusion of the hemangioma.
  • Case 2 had 3 photodynamic therapy treatments.
  • The hemangioma was fibrotic, and 20 months after initiating photodynamic therapy visual acuity improved to 20/30.
  • Case 3 had 1 treatment, 11 weeks later and visual acuity improved to 20/400.
  • Four months after treatment, visual acuity returned to counting fingers because of tractional elevation of the macula as the capillary hemangioma fibrosed.
  • Vitrectomy surgery was performed, and choroidal and retinal neovascularization was discovered.
  • In cases 1 and 2, the capillary hemangioma ultimately regressed, and the exudative detachment resolved.
  • CONCLUSIONS: Verteporfin and photodynamic therapy were effective in achieving closure of large retinal capillary hemangiomas.
  • In all cases, the hemangioma underwent fibrosis with consequent macular puckering due to retinal traction.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Female. Fibrosis. Humans. Male. Retinal Vessels / drug effects. Retinal Vessels / pathology. Treatment Outcome. Visual Acuity. Vitrectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767474.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / 5P30EY006360
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


3. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology; 2002 Jul;109(7):1256-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefits and complications of photodynamic therapy of papillary capillary hemangiomas.
  • OBJECTIVE: To evaluate the potential benefit and risks of photodynamic therapy (PDT) in the treatment of papillary capillary hemangioma.
  • PARTICIPANTS: Five patients with solitary capillary hemangioma on the temporal portion of the optic nerve presenting with exudative decompensation and decrease in visual acuity (VA).
  • METHODS: All eyes received a standardized PDT treatment with 6 mg/kg body surface area verteporfin and application of 100 J/cm(2) light at 692 nm.
  • A continuous follow-up was provided with documentation 1 week before and at 4 to 6 weeks, 3 months, and 12 months after the last treatment application.
  • MAIN OUTCOME MEASURES: Functional parameters included best-refracted VA (Early Treatment Diabetic Retinopathy Study), and central scanning laser ophthalmoscope (SLO) scotometry and peripheral (automated perimetry) visual fields; anatomic parameters were presence of retinal edema or serous detachment (ophthalmoscopy) and tumor size (ultrasonography).
  • Tumor regression with resolution of macular exudate and serous retinal detachment was obtained in all eyes.
  • Complications included transient decompensation of vascular permeability, occlusion of retinal vessels, and ischemia of the optic nerve.
  • Vaso-occlusive effects at the level of the retina and optic nerve compromise the functional benefit.
  • Parameters proven safe in choroidal neovascularization may be inappropriate in retinal capillary lesions of the optic nerve.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Optic Disk / blood supply. Optic Nerve Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Capillary Permeability / drug effects. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Ophthalmoscopy. Optic Neuropathy, Ischemic / chemically induced. Prospective Studies. Retinal Artery Occlusion / chemically induced. Retinal Vein Occlusion / chemically induced. Visual Acuity. Visual Fields

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12093647.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


Advertisement
4. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E: Photodynamic therapy for vasoproliferative retinal tumors. Retina; 2006 Apr;26(4):404-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for vasoproliferative retinal tumors.
  • PURPOSE: To report our experience with photodynamic therapy (PDT) with verteporfin for patients with vasoproliferative retinal tumors (VPRTs).
  • Biomicroscopy, fluorescein angiography, indocyanine green angiography, optical coherence tomography, and ultrasonography were performed before treatment and 1 month, 3 months, 6 months, and 1 year after treatment; visual acuity was measured using Early Treatment Diabetic Retinopathy Study criteria.
  • RESULTS: At the 1-year follow-up, all tumors responded with a reduction in size (mean height: pretreatment, 2.96 mm; posttreatment, 1.32 mm), and optical coherence tomography showed complete resolution of macular exudates.
  • An improvement in visual acuity (average, 4.7 Early Treatment Diabetic Retinopathy Study letters) was observed.
  • CONCLUSION: PDT may represent an effective and safe modality of treatment for VPRTs because of its selectivity.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Coloring Agents. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Retinal Hemorrhage / diagnosis. Retinal Hemorrhage / drug therapy. Retinal Vessels / drug effects. Tomography, Optical Coherence. Visual Acuity

  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603958.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


5. Toyokawa N, Kimura H, Kuroda S: Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide. Jpn J Ophthalmol; 2010 Mar;54(2):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Glucocorticoids / therapeutic use. Hemangioma, Capillary / drug therapy. Optic Nerve Neoplasms / drug therapy. Triamcinolone Acetonide / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Therapy, Combination. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Injections. Optic Disk. Retinal Hemorrhage / diagnosis. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vitreous Body

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2000 Dec;107(12):2240-8 [11097604.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):48-54 [10647718.001]
  • [Cites] Ophthalmology. 2002 Jul;109 (7):1256-66 [12093647.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1015-22 [9402176.001]
  • [Cites] Retina. 2007 Feb;27(2):150-8 [17290195.001]
  • (PMID = 20401570.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glucocorticoids; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down






Advertisement